Nearly 30,000 smokers took part in trials testing the best way to quit, and nicotine e-cigarettes beat every other method tested.
Quick Take
- Cochrane’s updated review covers 80 randomized trials and 29,861 participants, the largest evidence base yet on quitting smoking.
- Nicotine e-cigarettes helped about 4 more people per 100 quit compared to patches and gum.
- The same review found nicotine vapes beat non-nicotine vapes by about 2 more quitters per 100.
- The findings arrive as the FDA faces separate questions about fruit-flavored vapes and youth access.
What The Largest Review Of Quitting Methods Actually Found
Cochrane, the nonprofit famous for grading medical evidence, updated its living review on smoking cessation. The analysis pulled together 80 randomized controlled trials involving 29,861 people, adding nine new trials since the last update. That size matters. Small studies can mislead. A pool this large, built from trials where researchers randomly assigned people to different quit methods, gives doctors and regular smokers a much clearer picture of what actually works.
The headline number is simple. Nicotine e-cigarettes produced about 4 more quitters per 100 people than nicotine-replacement therapy, the patches and gum sold in every pharmacy for decades. Cochrane rated this high-certainty evidence, its strongest confidence label. Nicotine vapes also beat non-nicotine vapes by about 2 more quitters per 100, showing the nicotine itself carries real weight in helping smokers break the habit. A separate Cochrane dataset backs this up, showing nicotine e-cigarettes nearly doubling cessation odds compared to no intervention at all across 16 trials and 3,828 participants.
Cochrane frames this as a living review, meaning it gets updated as new trials appear rather than sitting frozen for years. That matters for smokers and doctors trying to make real-time decisions. It also means today’s numbers could shift again once more trials finish, which is simply how good science works over time.
Why This Collides With The Fight Over Flavored Vapes
This cessation data lands right as the Food and Drug Administration (FDA) navigates a separate, thornier fight over flavored e-cigarettes. In May 2026, the agency authorized four Glas-brand products, including mango and blueberry flavors, for legal marketing. Boston University’s School of Public Health has questioned whether that call serves public health or undermines it. The Cochrane data speaks to nicotine vapes broadly. It does not prove fruit flavors specifically help adults quit better than tobacco-flavored options.
The American Dental Association pressed the FDA to rethink its approval pathway for flavored products entirely. The American Association for Cancer Research went further, warning that flavored vapes carry greater youth appeal than tobacco-flavored ones. These aren’t fringe objections. They point to a real tension: a product that helps a 50-year-old pack-a-day smoker quit might simultaneously be the exact flavor that hooks a 15-year-old who never smoked at all.
The National Academies summed up this tradeoff years ago, noting e-cigarettes may boost adult quitting while also raising the odds that teens who vape later pick up combustible cigarettes. Flavors sit at the center of that tradeoff because they drive both appeal and abuse potential. A conservative read of this data respects parental authority and personal responsibility for adults making informed choices, while still demanding the FDA keep youth access locked down tight through age verification and marketing limits.
What Smokers And Parents Should Take From This
The American Lung Association has pointed out that the FDA has never formally approved an e-cigarette as a smoking-cessation medication the way it approved patches or gum. That’s a real regulatory distinction. Marketing authorization and medical approval are not the same thing, even though Cochrane’s trial data suggests vapes work better in practice than either approved option currently on pharmacy shelves.
For an adult smoker weighing options, the evidence now clearly favors nicotine vaping over patches or gum for raw quit rates. For a parent, the flavor question remains unsettled, and that gap deserves more product-specific research before anyone declares total victory. Both things can be true at once, and pretending otherwise does a disservice to the millions of American families navigating this decision in real life.
Sources:
sciencedaily.com, cochrane.org, lung.org, bu.edu
